Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harte-HanksHHS +1.53%61 Days Sales Outstanding is 83.73 as of Jun. 2026, which is 12% above its 10-year median of 74.83. GuruFocus rates HHS with a GF Score™ of 61/100 and a GF Value™ of $4.13 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 525 Conglomerates companies, Harte-Hanks ranks worse than 62.1% on this metric.
Harte-Hanks's average Accounts Receivable for the
three
months ended in Jun. 2026 was $34.9 Mil. Harte-Hanks's Revenue for the
three
months ended in Jun. 2026 was $38.0 Mil.
Hence, Harte-Hanks's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 83.72.
The historical rank and industry rank for Harte-Hanks's Days Sales Outstanding or its related term are showing as below:
HHS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.98 Med: 74.83 Max: 86.97
Current: 68.93
During the past 13 years, Harte-Hanks's highest Days Sales Outstanding was 86.97. The lowest was 64.98. And the median was 74.83.
HHS's Days Sales Outstanding is ranked worse than 62.1% of 525
companies
in the Conglomerates industry
Industry Median: 56.75
vs HHS: 68.93
Harte-Hanks's Days Sales Outstanding
declined
from Jun. 2025 (95.66) to Jun. 2026 (83.73).
Harte-Hanks (NAS:HHS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Harte-Hanks Days Sales Outstanding Related Terms
Harte-Hanks Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Harte-Hanks's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HHS vs GPUS, LGPS, PLAG: Days Sales Outstanding Comparison
For the Conglomerates subindustry, Harte-Hanks's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harte-Hanks Days Sales Outstanding vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Harte-Hanks's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Harte-Hanks's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harte-Hanks (HHS) has a Days Sales Outstanding of 83.73 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Harte-Hanks and its competitors. This is 12% above median its historical median of 74.83. Over the past decade, Harte-Hanks' Days Sales Outstanding has ranged from 64.98 to 86.97. According to the industry distribution chart, Harte-Hanks ranks #326 out of 525 companies in the Conglomerates industry, placing it in the top 62.1%.
Is Harte-Hanks' Days Sales Outstanding too high?
Harte-Hanks' current Days Sales Outstanding of 83.73 is 12% above median its 10-year median of 74.83. Over the past 10 years, this metric has ranged from a low of 64.98 to a high of 86.97. The Conglomerates industry median Days Sales Outstanding is 56.75. Harte-Hanks' value of 83.73 is 47.5% above this industry median. Based on the distribution chart, Harte-Hanks ranks #326 out of 525 companies in the Conglomerates industry, which is below the industry midpoint. Overall, Harte-Hanks has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harte-Hanks' Days Sales Outstanding compare to GPUS and LGPS?
According to the Conglomerates industry distribution chart, Harte-Hanks ranks #326 out of 525 companies for Days Sales Outstanding. This places Harte-Hanks in the lower half of its industry. The industry median Days Sales Outstanding is 56.75. Harte-Hanks' value of 83.73 is 47.5% above this benchmark. Historically, Harte-Hanks' own Days Sales Outstanding has ranged from 64.98 to 86.97 over the past decade. While the company's 10-year median is 74.83 vs. the industry median of 56.75, Harte-Hanks has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Conglomerates company?
The median Days Sales Outstanding among Conglomerates companies is 56.75, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harte-Hanks's current Days Sales Outstanding of 83.73 is 47.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Harte-Hanks and its competitors. For the Conglomerates industry, the median Days Sales Outstanding is 56.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harte-Hanks's current Days Sales Outstanding is 83.73, which is 12% above median its own 10-year median of 74.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harte-Hanks stock overvalued right now?
Based on GuruFocus' analysis, Harte-Hanks (HHS) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.13, compared to a current price of $4.64 — trading 12.3% above its estimated fair value. The current Days Sales Outstanding is 83.73, which is 12% above median its 10-year median of 74.83 and 47.5% above the Conglomerates industry median of 56.75. Harte-Hanks' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Harte-Hanks (HHS), the current Days Sales Outstanding is 83.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harte-Hanks (HHS) Overvalued in 2026?
Based on GuruFocus' analysis, Harte-Hanks stock appears to be overvalued.
The current stock price of $4.64 is trading 12.3% above its estimated GF Value™ of $4.13.
GuruFocus considers Harte-Hanks to be Modestly Overvalued.
Key valuation signals for HHS:
Days Sales Outstanding: 83.73 (12% above median its 10-year median of 74.83)
GF Value™: $4.13 vs. price of $4.64 (12.3% above fair value)
Industry Position: 47.5% above the Conglomerates median (#326 of 525)
No single metric tells the full story. See the HHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
61GF Score
Get the complete analysis for HHS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HHS has been successfully added to your 
